163 related articles for article (PubMed ID: 32718999)
1. Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.
Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
Naz S; Leiker AJ; Choudhuri R; Preston O; Sowers AL; Gohain S; Gamson J; Mathias A; Van Waes C; Cook JA; Mitchell JB
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1295-1305. PubMed ID: 33838214
[TBL] [Abstract][Full Text] [Related]
3. The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.
Spiegelberg D; Dascalu A; Mortensen AC; Abramenkovs A; Kuku G; Nestor M; Stenerlöw B
Oncotarget; 2015 Nov; 6(34):35652-66. PubMed ID: 26452257
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of HSP90 inhibition in an in vivo squamous cell carcinoma model.
Spiegelberg D; Mortensen AC; Selvaraju RK; Eriksson O; Stenerlöw B; Nestor M
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):974-982. PubMed ID: 26627081
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach.
Spiegelberg D; Abramenkovs A; Mortensen ACL; Lundsten S; Nestor M; Stenerlöw B
Sci Rep; 2020 Apr; 10(1):5923. PubMed ID: 32246062
[TBL] [Abstract][Full Text] [Related]
6. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
[TBL] [Abstract][Full Text] [Related]
7. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
[TBL] [Abstract][Full Text] [Related]
8. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.
Do K; Speranza G; Chang LC; Polley EC; Bishop R; Zhu W; Trepel JB; Lee S; Lee MJ; Kinders RJ; Phillips L; Collins J; Lyons J; Jeong W; Antony R; Chen AP; Neckers L; Doroshow JH; Kummar S
Invest New Drugs; 2015 Aug; 33(4):921-30. PubMed ID: 26082332
[TBL] [Abstract][Full Text] [Related]
10. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors.
Shapiro GI; Kwak E; Dezube BJ; Yule M; Ayrton J; Lyons J; Mahadevan D
Clin Cancer Res; 2015 Jan; 21(1):87-97. PubMed ID: 25336693
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
[No Abstract] [Full Text] [Related]
12. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program.
Kang MH; Reynolds CP; Houghton PJ; Alexander D; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Maris JM; Wozniak A; Smith MA
Pediatr Blood Cancer; 2012 Jul; 59(1):185-8. PubMed ID: 21538821
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
Wagner AJ; Agulnik M; Heinrich MC; Mahadevan D; Riedel RF; von Mehren M; Trent J; Demetri GD; Corless CL; Yule M; Lyons JF; Oganesian A; Keer H
Eur J Cancer; 2016 Jul; 61():94-101. PubMed ID: 27156227
[TBL] [Abstract][Full Text] [Related]
14. Induction of Heat Shock Protein 70 as a Predictive Marker of the Tumor Cell Radiosensitization with Inhibitors of the Heat Shock Protein 90 Activity.
Kudryavtsev VA; Khokhlova V AV; Mosina A; Makarova YM; Kabakov AE
Radiats Biol Radioecol; 2016 Sep; 56(5):494-502. PubMed ID: 30703309
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Do KT; O'Sullivan Coyne G; Hays JL; Supko JG; Liu SV; Beebe K; Neckers L; Trepel JB; Lee MJ; Smyth T; Gannon C; Hedglin J; Muzikansky A; Campos S; Lyons J; Ivy P; Doroshow JH; Chen AP; Shapiro GI
Cancer Chemother Pharmacol; 2020 Dec; 86(6):815-827. PubMed ID: 33095286
[TBL] [Abstract][Full Text] [Related]
16. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
17. Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Xu J; Wu PJ; Lai TH; Sharma P; Canella A; Welker AM; Beattie CE; Elder JB; Easley M; Lonser R; Jacob NK; Pietrzak M; Timmers CM; Lang F; Sampath D; Puduvalli VK
Clin Cancer Res; 2022 May; 28(9):1979-1990. PubMed ID: 35140124
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
[TBL] [Abstract][Full Text] [Related]
19. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.
Kinzel L; Ernst A; Orth M; Albrecht V; Hennel R; Brix N; Frey B; Gaipl US; Zuchtriegel G; Reichel CA; Blutke A; Schilling D; Multhoff G; Li M; Niyazi M; Friedl AA; Winssinger N; Belka C; Lauber K
Oncotarget; 2016 Jul; 7(28):43199-43219. PubMed ID: 27259245
[TBL] [Abstract][Full Text] [Related]
20. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
Schilling D; Garrido C; Combs SE; Multhoff G
Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]